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CalcilyticThe inverse correlation between dietary calcium intake and the risk of colorectal cancer (CRC) iswell known, but
poorly understood. Expression of the calcium-sensing receptor (CaSR), a calcium-binding G protein-coupled
receptor is downregulated in CRC leading us to hypothesize that the CaSR has tumor suppressive roles in the
colon. The aim of this study was to understand whether restoration of CaSR expression could reduce the
malignant phenotype in CRC.
In human colorectal tumors, expression of the CaSR negatively correlated with proliferation markers whereas
loss of CaSR correlated with poor tumor differentiation and reduced apoptotic potential. In vivo, dearth of CaSR
signiﬁcantly increased expression of proliferation markers and decreased levels of differentiation and apoptotic
markers in the colons of CaSR/PTH double knock-out mice conﬁrming the tumor suppressive functions of CaSR.
In vitro CRC cells stably overexpressing wild-type CaSR showed signiﬁcant reduction in proliferation, as well as
increased differentiation and apoptotic potential. The positive allostericmodulator of CaSR, NPS R-568 further en-
hanced these effects, whereas treatment with the negative allosteric modulator, NPS 2143 inhibited these func-
tions. Interestingly, the dominant-negative mutant (R185Q) was able to abrogate these effects.
Our results demonstrate a critical tumor suppressive role of CaSR in the colon. Restoration of CaSR expression and
function is linked to regulation of the balance between proliferation, differentiation, and apoptosis and provides a
rationale for novel strategies in CRC therapy. This article is part of a Special Issue entitled: 13th European sympo-
sium on calcium.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Garland et al. demonstrated an inverse correlation between dietary
calcium (Ca2+) intake and the risk of colorectal cancer (CRC), identify-
ing nutritional Ca2+ as a promising chemopreventive agent [1]. SinceaSR, calcium-sensing receptor;
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állay).
. This is an open access article underthen several advances have been made with focus on studies trying to
establish risk factors to facilitate suitable intervention in CRC [1–3].
In the colon, Ca2+ exerts its functions through various mechanisms,
including binding toxic bile acids and ionized fatty acids, to form
insoluble soaps or by regulating cellular proliferation, inducing differen-
tiation and/or stimulating apoptosis [4–12]. However these anti-
tumorigenic effects of Ca2+ fail during tumor progression. Although it is
clear that Ca2+ exerts chemopreventive features in the colon, the molec-
ular mechanisms by which extracellular Ca2+ modulates cell fate are not
fully understood. Finding markers that would allow us to distinguish
between an individual's responsiveness to calcium, or a target that
could be modulated to restore responsiveness is of utmost importance.
The calcium-sensing receptor (CaSR) has been identiﬁed as a key
molecule in regulating systemic calciumhomeostasis in the parathyroid
[13]. The CaSR gene encodes a calcium-binding G protein-coupled
receptor (GPCR), with an extracellular N-terminal domain (containing
the calcium binding sites), joined to the C-terminal domain via a
seven transmembrane region (essential for its signaling function).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Clinicopathological characteristics of the patient cohort.
Patient characteristics
Number 54
Gender
Male 28
Female 26
Age (Mean ± SD) 68.7 ± 12.2
Tumor grading
Grade 1 1
Grade 2 51
Grade 3 1
Unknown 1
Tumor staging
Stage 1 11
Stage 2 17
Stage 3 25
Stage 4 1
Lymph node inﬁltration
0 27
1 13
2 11
3 1
Unknown 2
Site of primary tumor
Cecum/ascending/transverse 22
Descending/sigmoid 19
Rectum 13
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main of the receptor [14]. Several synthetic modulators of the CaSR
have been developed in order to modulate CaSR function. Calcimimetic
agents like NPS R-568 are positive allosteric modulators of the CaSR,
which potentiate the effects of the CaSR by interacting with the 7-
transmembrane region of the receptor and inducing conformational
changes. Calcilytic agents (e.g. NPS 2143) that are negative allosteric
modulators of the receptor act in a similar manner, desensitizing the
receptor, and reducing its afﬁnity to its ligands [14,15].
There is strong evidence for the involvement of the CaSR in various
functions determining cellular fate [4,16,17]. These functions extend
beyond the control of calcium homeostasis; the primary function of
the CaSR. It has been suggested that the CaSR is either a tumor suppres-
sor (e.g. in colon and parathyroid) or an oncogene (e.g. in breast and
prostate) depending on the site of disease [18]. Expression of colonic
CaSR is signiﬁcantly downregulated during colorectal tumorigenesis
[19–21] at least in part, by aberrant DNA methylation and histone
deacetylation [19,22]. CRC cells that lack the CaSR have a highly malig-
nant phenotype [23]. Taken together, the epidemiological observation
of the inverse relationship between Ca2+ intake and risk of CRC, the ob-
servation that CaSR mRNA and protein expression is reduced in human
colon tumors, and the observations that CRC cells lacking the CaSR have
a malignant phenotype lead to the hypothesis that the CaSR is a tumor
suppressor in the colon. However, there are only limited or no data in
support of a causal relationship between CaSR expression and de-
differentiation and carcinogenesis.
In this study we present evidence that the CaSR is a tumor suppres-
sor in the colon using three distinct approaches: ex vivo, in vivo and in
vitro. These models have allowed us to investigate the role of the
receptor in the colon and to understand whether restoration of CaSR
function can prevent or attenuate the malignant phenotype in CRC.
2. Materials and methods
2.1. Human patient samples
Fresh frozen tumor tissue and adjacent non-tumor tissue from
54 CRC patients were obtained after written consent. Samples were col-
lected from the General Hospital of Vienna and Rudolfstiftung Hospital
in Vienna and snap frozen in liquid nitrogen. A pathologist graded and
classiﬁed the samples according to the TNM system. Approval by the
local ethics committees was obtained prior to the start of the study.
Clinicopathological characteristics of the patient cohort are shown in
Table 1.
2.2. Animals
Mice heterozygous for CaSRΔExon5 and PTH were bred to generate
CaSR+/+/PTH−/− and CaSR−/−/PTH−/−mice as previously described
[24]. Ethics approval was obtained from the Institutional Animal
Care and Use Committee at Harvard Medical School. Mice were fed
standard mouse chow (Harlan Teklad-TD99224, Harlan-Teklad,
USA). Age- and sex-matched animals (n = 9/genotype) were
sacriﬁced, the colons were washed in ice cold PBS and stored in
RNAlater (Life Technologies, Austria) until RNA extraction was
carried out. For the analysis, 1–2 cm of colonic tissue 0.5 cm distal
from cecum was used.
2.3. RNA isolation, reverse transcription and quantitative-reverse
transcription PCR (qRT-PCR)
Total RNAwas isolated using TRIzol (Life Technologies) according to
the manufacturer's instructions. RNA integrity was checked by agarose
gel electrophoresis, and total RNAwas reverse transcribed as previously
described [25]. qRT-PCR was performed using POWER SYBR Green
Mastermix (Life Technologies) on a StepOne Plus qRT-PCR machine(Life Technologies). Where possible, primers were designed to bridge
an exon–exon junction to prevent genomic DNA from being ampliﬁed.
TheΔΔCtmethodwas used to calculate fold changes in gene expression,
relative to housekeeping genes (human beta-actin (hβ-ACTIN) for
human patient samples; hβ-ACTIN, human large ribosomal protein
(hRPLPO) and human beta-2-microglobulin (hβ2M) for human cell
lines; mβ-Actin and mouse eukaryotic translation elongation factor 1
beta 2 (mEef1b2) for mouse colon samples) and normalized to a com-
mercially available total RNA calibrator (Clontech, USA). Primer se-
quences are described in Supplementary Table S1. Primer sequences
for hCDC6, hMCM2, hβ-ACTIN, hRPLPO and hβ2M have been previously
described [19,25].
2.4. Cell culture
The human CRC cell lines Caco2-15 and HT29 were used in this
study. HT29 cells were obtained from American Type Culture Collection
(ATCC, USA). The Caco2-15 cells are a sub-clone of Caco2 cells [26] and
were kindly provided by Prof. A Quaroni (Cornell University, USA). Cells
were regularly maintained in Dulbecco's Modiﬁed Eagle's Medium
(DMEM) containing 10% fetal bovine serum (FBS) as previously de-
scribed [19]. Ca2+ concentration in the medium was 1.8 mM, unless
otherwise stated. Cells were routinely tested for mycoplasma contami-
nation using the VenorGem Mycoplasma Detection Kit (Minerva
Biolabs, Germany) and were periodically authenticated by STR DNA
proﬁling (DNA Diagnostic Center, UK).
2.5. Cloning of the human CaSR cDNA
pcDNA3.1 expression vector encoding a full length wild-type CaSR
(CaSR-WT) was kindly provided by Dr. AL Magno and Prof. BK Ward
(University of Western Australia, Nedlands). hCaSR cDNA was sub-
cloned into the HindIII and XbaI restriction enzyme sites of the
pcDNA™3.1/Zeo(+) expression vector (Life Technologies). The hCaSR
sequence was FLAG-tagged in its C-terminal region using a reverse
primer designed to contain, in the 5′ to 3′ direction, theXbaI recognition
sequence, the wild-type stop codon sequence, the sequence encoding
the FLAG peptide (GACTACAAGGACGACGATGACAAG), and the hCaSR
sequence adjacent to the wild-type stop codon. Another set of primers
was then used to generate the R185Q dominant negative mutant of
2160 A. Aggarwal et al. / Biochimica et Biophysica Acta 1853 (2015) 2158–2167the hCaSR (CaSR-DN), using the FLAG tagged hCaSR as a template. After
PCR ampliﬁcation, appropriately digested PCR products were cloned
into HindIII/XbaI digested pcDNA™3.1/Zeo(+). Sequence ﬁdelity of the
PCR products was checked by sequence analysis.
2.6. Cloning and stable transfection of plasmids in Caco2-15 and HT29 cells
Plasmid constructs were cloned using either One Shot® MAX
Efﬁciency® DH5α™-T1R Competent E. coli Cells or Topo TA Cloning Kit
and electro-competent E. coli bacteria following the manufacturer's
protocol. Midipreps were performed with PureLink® HiPure Plasmid
Midiprep Kit (all Life Technologies).
HT29 and Caco2-15 cells were cultured in 24-well plates to 50–60%
conﬂuency. Non-linearized plasmid midipreps were transfected using
Lipofectamine™ LTX (Life Technologies) [Caco2-15 (500 ng/well plas-
mid, 1.25 μl Lipofectamine™ LTX) and HT29 (750 ng/well plasmid,
2.5 μl Lipofectamine™ LTX)] for 48 h. After transfection, cells were
cultured in the presence of Zeocin (Caco2-15: 75 μg/ml and HT29:
150 μg/ml) for over six months to select stably transfected cells.
2.7. Sequencing DNA from stably transfected Caco2-15 and HT29 cells
DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen,
Germany) according to the manufacturer's instructions. Standard PCR
was used to amplify exon 4 of CaSR gene using Taq polymerase: initial
denaturation at 95 °C for 2 min, 30 cycles of denaturation at 97 °C for
30 s, annealing at 65 °C for 60 s, extension at 72 °C for 90 s followed
by elongation at 72 °C for 7 min and termination at 4 °C. PCR products
were sequenced using the Genetic Analyzer 3130xI (Life Technologies).
Primers used were GGCTCTTCTACATTCAG (Fwd) and GAATTCCCGGAA
GCCTGGGATCTGC (Rev).
2.8. Immunostaining
Cells were stained to detect CaSR expression using a monoclonal
antibody against the ADD region in the N-terminal domain of the
CaSR sequence. Cells grown on glass cover slipswere ﬁxed in 3.7% para-
formaldehyde for 20 min, permeabilized with 0.2% Triton-X for 20 min,
and blocked with 5% goat serum for 30 min. Cells were incubated with
anti-CaSR antibody (1:200, Abcam, UK) for 1 h at room temperature.
After extensive washing, samples were incubated with Alexa Fluor
647 goat-anti-mouse antibody (1:1000, Life Technologies). Nuclei
were stained with DAPI (1:3000, Roche, Switzerland). Whole slide
images were acquired using TissueFAXS (TissueGnostics, Austria).Tumor
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Fig. 1. Expression of theCaSR andmarkers of neoplastic transformation in colorectal tumors. Tum
for gene expression of the CaSR, the proliferationmarkers CDC6, CDT1,MCM2,MCM4,MCM6,M
interquartile range and whiskers representing 5th to 95th percentile are shown. Statistical signIsotype-speciﬁc IgG was used as negative control and human kidney
tissue was stained as positive control.
2.9. Growth curve assay
Cells were plated in triplicates (initial seeding density: Caco2-15:
5000 cells/cm2; HT29: 7500 cells/cm2) in 96 well plates in regular
growth medium. Cells were harvested after 24, 48 and 72 h in culture.
To overcome the possible differences in plating efﬁciencies between
genotypes, data were normalized to the number of viable cells 24 h
post-seeding. Doubling time was calculated using the web tool at
www.doubling-time.com/compute.php. The assay was performed at
least in three independent experiments.
2.10. Functional assays
Cells were cultured in the normal growth medium. One week post-
conﬂuence, medium was changed to serum-free DMEM supplemented
with 5 mg/ml insulin, 5 mg/ml transferrin, and 5 ng/ml sodium selenite
(ITS, Life Technologies) as previously described [4]. Cells were treated
with the allosteric modulators of CaSR [NPS R-568 (1 μM in DMSO) or
NPS 2143 (1 μM in DMSO)] for 48 h. Medium contained 1.8 mM Ca2+
unless otherwise stated. Vehicle-treated cells were used as controls in
all experiments.
Proliferation was measured by counting viable cells as previously
described [19] with the T10 automated cell counter (BioRad, USA).
Differentiation was determined using the Alkaline Phosphatase (ALP)
Colorimetric AssayKit (Abcam). ALP activity per 105 cellswas calculated
and data presented in units/ml. In HT29 cells, differentiation was mea-
sured using qRT-PCR tomeasuremRNA expression of the differentiation
markers, sucrase isomaltase and caudal type homeobox 2 (CDX2).
Apoptosis was evaluated using the Apo-ONE Homogeneous Caspase
3/7 Assay Kit (Promega, Germany), and data were normalized
to the number of viable cells. All assays were performed according
to the manufacturer's instructions and repeated at least in three
independent experiments.
2.11. Statistical analysis
Paired t-tests were computed to compare the expression of genes
between tumor and adjacent non-tumor samples of the same patient.
Correlation analysis was performed using the nonparametric Spearman
correlation test. For group comparison, Analysis of Variance (ANOVA)
tests were performed followed by Tukey's post-test. Non-normallyAdjacent Mucosa
4 MCM6 MCM7 CDC45 SI BAX
*** *** *** *** ***
or samples (mainly grade 2) and adjacentmucosa from54 CRC patientswere investigated
CM7, and CDC45, the differentiationmarker SI and the pro-apoptoticmarker BAX.Median,
iﬁcance was calculated using paired t-tests. ***p b 0.001.
Table 2
Correlation between expression of the CaSR and markers of neoplastic transformation
in colorectal tumors. Spearman correlation coefﬁcient (SCC) and p-value are shown.
Function SCC p value
CDC6 DNA replication −0.502 b0.001
CDT1 DNA replication −0.401 b0.001
MCM2 DNA replication −0.369 b0.001
MCM4 DNA replication −0.341 b0.001
MCM6 DNA replication −0.481 b0.001
MCM7 DNA replication −0.437 b0.001
CDC45 DNA replication −0.500 b0.001
SI Differentiation 0.540 b0.001
BAX Apoptosis 0.310 b0.001
2161A. Aggarwal et al. / Biochimica et Biophysica Acta 1853 (2015) 2158–2167distributed data were log-transformed to achieve normal distribution. p
values b0.05 were considered statistically signiﬁcant. SPSS (IBM, USA)
was used to perform all statistical calculations and graphs were plotted
using GraphPad Prism (GraphPad Software Inc., USA).Mcm2
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Fig. 2. Effect of colonic CaSR on regulation of genes modulating proliferation, differentiation, a
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3.1. CaSR mRNA expression positively correlates with the expression of
differentiation and pro-apoptotic markers, and negatively correlates with
proliferation markers in CRC patients
Expression of the CaSR is signiﬁcantly down-regulated in CRC,
possibly impairing the anti-tumorigenic effects of Ca2+. To predict if
loss of CaSR in CRC is linked to tumorigenesis, we performed correlation
analyses between CaSR expression and genes regulating neoplastic
transformation in tumor samples (mainly grade 2) from54 CRC patients
(Table 1), compared with samples of the adjacent non-tumorous
mucosa from the same patient. We examined the mRNA expression of
a ‘DNA replication signature’ that has been previously reported to be
deregulated in transformed colon [27]. DNA replication factors cell
division cycle 6 (CDC6), chromatin licensing and DNA replication factor
1 (CDT1), mini chromosomal maintenance complex (MCM2, MCM4,
MCM6, MCM7) and CDC45 were all signiﬁcantly up-regulated in
tumor samples comparedwith the adjacentmucosa of the same patientCdc6
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.
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negative correlation between CaSR expression and the expression of
the DNA replication genes (p b 0.001, Table 2). As N90% of our patient
cohort (51 out of 54, Table 1) were of grade 2, and we had only one
stage IV patient with distant metastasis, we were unable to assess a
correlation between CaSR expression and tumor grade or stage.
The expression of the differentiation marker, sucrase isomaltase
(SI) and the pro-apoptotic marker, Bcl-2 associated X protein
(BAX) were signiﬁcantly down-regulated in the tumor samples com-
pared with the adjacent mucosa (n= 54, p b 0.001, Fig. 1). Spearman
correlation analyses showed signiﬁcant, positive correlation be-
tween CaSR expression and the expression of SI and BAX
(p b 0.001, Table 2).
3.2. CaSR regulates transcription of proliferation, differentiation and
apoptosis-related genes in vivo
We investigated the consequence of CaSR knock down in a mouse
model in which exon-5 of the CaSR gene is globally ablated on a PTH-
null background to prevent the development of catastrophic primary
hyperparathyroidism. qRT-PCR using primers targeting the junction of
exons 4 and 5 of CaSR conﬁrmed lack of CaSR mRNA expression in the
colons of CaSR−/−/PTH−/− (DKO) mice compared with CaSR+/+/
PTH−/− (control) mice (n = 9 animals/genotype, Fig. 2A).
The mRNA expression of genes of the ‘DNA replication signature’
(origin recognition complex 1 (Orc1), Cdc6, Cdc45, Mcm2, Mcm5, and
Mcm6) was signiﬁcantly upregulated in mice lacking the CaSR (DKO,
Fig. 2B–G). In contrast, the differentiation marker sucrase isomaltase
(Fig. 2H), and the pro-apoptotic marker, Bax (Fig. 2I) were signiﬁcantly
downregulated in the colons of these DKO mice.
Taken together, the data from the ex vivo and the in vivo study show
that colonic cells with reduced CaSR expression have a signiﬁcant
derangement in molecular markers of neoplastic progression.
3.3. Stable transfection of Caco2-15 and HT29 cells
We studied the effect of CaSR on hallmarks of cancer in two CRC cell
lines: the Caco2-15 cells representative of differentiated tumors, and
the highly malignant HT29 cells representative of undifferentiated
tumors [26,28,29]. Endogenous CaSR expression is negligible in HT29Fig. 3. Conﬁrmation of transfection in CRC cell lines. Expression of CaSR protcells but detectable in Caco2-15 cells. We stably transfected the
Caco2-15 and HT29 cells with plasmids containing either a full-length
wild-type CaSR (CaSR-WT), or a functionally inactive dominant nega-
tive mutant (R185Q, CaSR-DN). Cells transfected with the empty
pcDNA™3.1/Zeo(+) plasmid (EMP) served as controls.
Sequence ﬁdelity of the plasmidswas conﬁrmed by sequence analy-
sis. DNA sequencing of exon 4 of the CaSR gene conﬁrmed successful in-
tegration of transfected vectors. CaSR-DN cells expressed the R185Q
mutation, whereas CaSR-WT cells expressed the wild-type sequence
(Gene Id: 846). PCR using primers directed against the region
encompassing the FLAG peptide and exon 7 to exclude ampliﬁcation
of endogenous CaSR conﬁrmed transfections of all 3 constructs in both
cell lines (data not shown). Immunostaining using anti-CaSR antibody
showed basal CaSR protein in Caco2-15EMP cells whereas HT29EMP
cells did not exhibit any CaSR immuno-reactivity. Upregulation of
CaSR protein was seen in cells overexpressing CaSR-WT and CaSR-DN
constructs, in both cell lines (Fig. 3).3.4. CaSR modulates growth kinetics of colon cancer cells
To assess the effects of the expression of the various constructs,
stably transfected cells were seeded in normal growth medium and
viable cells were counted 48 and 72 h post-seeding.
Both, HT29 and Caco2-15 cells overexpressing the CaSR-WT
construct grew signiﬁcantly slower than control cells transfected with
the empty vector, whereas cells expressing the CaSR-DN grew signiﬁ-
cantly faster (p b 0.001, Fig. 4). Doubling time analysis was consistent
with these results (Table 3).3.5. Over-expression of CaSR inhibits proliferation and promotes apoptosis
and spontaneous differentiation in Caco2-15 cells
Ca2+ has been shown to have anti-neoplastic effects in the colon by
modulating anti-proliferative, pro-differentiating and pro-apoptotic
mechanisms. To further understand how the CaSR levels and function
inﬂuence the anti-tumorigenic properties of Ca2+, stably transfected
Caco2-15 cells were treated with either the calcimimetic NPS R-568,
or the calcilytic NPS 2143 for 48h to study how these speciﬁc CaSRmod-
ulators affect proliferation, spontaneous differentiation and apoptosis.ein as determined by immunoﬂuorescence. White bar represents 50 μm.
Table 3
Impact of stable transfectants on doubling times inHT29 and Caco2-15 cells. Statistical sig-
niﬁcance was determined by ANOVA followed by Tukey's post-test. p values indicate sig-
niﬁcant changes within groups (compared with EMP cells).
HT29 Caco2-15
Doubling time (h) p value Doubling time (h) p value
Empty 13.0 17.4
CaSR-WT 14.0 b0.001 20.9 b0.001
CaSR-DN 12.2 b0.001 16.2 b0.001
2163A. Aggarwal et al. / Biochimica et Biophysica Acta 1853 (2015) 2158–2167Proliferation decreased signiﬁcantly in the Caco2-15CaSR-WT cells and
in cells treated with the positive allosteric modulator NPS R-568
(Fig. 5A). These cells weremore differentiated (as assessed byALP activ-
ity, Fig. 5B) and had signiﬁcantly increased apoptotic potential (Fig. 5C)
compared with the Caco2-15EMP cells. Furthermore, Caco2-15CaSR-DN as
well as cells treated with the calcilytic showed signiﬁcantly decreased
sensitivity to Ca2+ as seen by increased cell number and decreased
ALP and Caspase3/7 activity (Fig. 5).
3.6. Over-expression of CaSR inhibits proliferation and promotes apoptosis
and differentiation in HT29 cells
To verify further the involvement of CaSR in inhibiting proliferation
and inducing apoptosis we treated the stably transfected HT29 cells
with either the calcimimetic NPS R-568, or the calcilytic NPS 2143 for
48 h.
The positive allosteric modulator, NPS R-568 signiﬁcantly decreased
cellular proliferation (assessed by viable cell count, Fig. 6A) and in-
creased apoptosis (assessed by Caspase3/7 activity, Fig. 6B) in cells
overexpressing the CaSR (HT29CaSR-WT) compared with the HT29EMP
cells. Furthermore, in comparison to HT29EMP cells, HT29CaSR-DN cells
as well as the cells treated with the calcilytic, NPS 2143 were less
sensitive to Ca2+ as seen by an increase in cell number, and decrease
in Caspase3/7 activity (Fig. 6).
Consistent with previous studies, HT29 cells exhibited extremely
low ALP activity in culture [28]. Therefore, we tested the impact of the
CaSR on differentiation by evaluating the mRNA expression of the
intestinal differentiation marker, sucrase isomaltase (SI) and caudal
type homeobox 2 (CDX2) in the stably transfected HT29 cells. We saw
a signiﬁcant upregulation of both markers in HT29CaSR-WT cells
compared with HT29EMP cells, whereas no difference was observed in
HT29CaSR-DN cells (Fig. 6C).
4. Discussion
Human and animal studies have shown that Ca2+ prevents crypt
hyperproliferation, suppresses dysplasia and protects the colon from
malignant transformation [5,30]. The calcium-sensing receptor (CaSR)
has been proposed as a potential mediator of these effects [6,31]. How-
ever, evidence for a causal relation between CaSR and colorectal tumor-
igenesis is still missing.
In the present studywe show that CaSR expression negatively corre-
lates with proliferation markers, but positively correlates with differen-
tiation and apoptosis markers in samples from human colorectal48h 72h
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Fig. 4. CaSR regulates growth kinetics of HT29 and Caco2-15 cells. Stably transfected cells were
with reduced proliferation rates. Overexpression of CaSR-DN however, was associated with in
controls. Data were normalized to number of viable cells 24 h post-seeding. Bars represent m
ANOVA followed by Tukey's post-test. Asterisks above bars indicate signiﬁcant changes withinadenocarcinomas. We demonstrate that knocking-down the CaSR in-
deed confers growth advantage to colonocytes in vivo. Finally, we pro-
duce evidence that restoration of CaSR function markedly suppresses
the tumorigenic phenotype of CRC cells in vitro increasing their apopto-
tic and differentiation potential. Our data indicate that the CaSR is a co-
lorectal tumor suppressor gene, which can be therapeutically targeted
for chemoprevention of CRC. Moreover, we show for the ﬁrst time,
that loss-of-function mutations of the CaSR might be a risk factor for
CRC.
Colonic CaSR expression is detected in normal mucosa, early adeno-
mas and polyps; it is already decreased in advanced adenomas, and
is almost undetectable in late stage, poorly differentiated tumors
[20–22]. In the present study, we observed positive correlation between
expression of the CaSR and expression of the differentiation marker SI
and the pro-apoptoticmarker BAX. SI is an independentmarker of prog-
nosis and survival in CRC patients [32,33]. Similarly, decreased expres-
sion of BAX predicts poor outcomes in CRC [34,35]. We show that
both of these factors are increased in cells expressing functional CaSR
supporting the hypothesis that downregulation of the CaSR is coupled
to tumor dedifferentiation in CRC. CaSR expression levels correlated
negatively with the DNA replication signature. This DNA replication sig-
nature, consisting of early replication genes, if upregulated during
colorectal tumorigenesis, predicts poor prognosis in CRC [27].
It is already known that in intestine-speciﬁc CaSR knockout mice,
the crypt architecture is disturbed and intestinal barrier function is im-
paired [17,36]. In the present study we observed signiﬁcant upregula-
tion in markers of proliferation, and a signiﬁcant downregulation of
markers of differentiation and apoptosis in DKO (CaSR−/−/PTH−/−)
mice compared with control (CaSR+/+/PTH−/−) mice. Strikingly, lack
of CaSR caused signiﬁcant dysregulation of pre-neoplastic genes in the
apparently normal colon samples fromDKOmice. Thesemice spontane-
ously develop aberrant crypt foci and have increased susceptibility to
dextran sulfate sodium-induced colitis [37]. In our study, the colonic tis-
sue contained not only the epithelial layer, but also the stroma and48h 72h
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groups (compared with EMP cells), *p b 0.05, ***p b 0.001.
Fig. 5. Impact of a CaSR activator or inhibitor on cell viability, differentiation, and apoptosis in stably transfected Caco2-15 cells. (A) Proliferation (n = 4), (B) apoptosis (n = 4) and
(C) differentiation (n = 3) were measured in Caco2-15CaSR-WT, Caco2-15CaSR-DN or the Caco2-15EMP cells. Bars represent means ± SEM. Statistical signiﬁcance was determined using
ANOVA followed by Tukey's post-test. Asterisks above bars indicate signiﬁcant differences within groups compared with the respective vehicle control (striped bars), whereas hash
tags indicate signiﬁcant differences between groups compared with Caco2-15EMP cells. *p b 0.01, **p b 0.05, ***p b 0.001, #p b 0.01 and ###p b 0.001.
2164 A. Aggarwal et al. / Biochimica et Biophysica Acta 1853 (2015) 2158–2167muscularis. However, based on the data from Rey et al. [17] and Cheng
et al. [36] using the intestine speciﬁc CaSR knock-out mouse as well as
the CaSR/PTH double knock out model used by MacLeod [37] it appears
that the CaSR in the epithelial cells is mainly responsible for these ef-
fects. Taken together, these data demonstrate that the CaSR is critical
for maintaining normal intestinal cell turnover.
Intestinal epithelial cells are sensitive to extracellular calcium. In
normal colonic epithelium, high calcium concentrations inhibit prolifer-
ation [5]. Epithelial cells at the bottom of the crypt proliferate optimally
in the presence of low calcium concentrations (0.05–0.1 mM). As thesecells begin to move up towards the crypt apex (where the calcium con-
centration reaches 0.8–2.2 mM), proliferation is turned off and the cells
begin to differentiate [6]. During tumor progression, colon cancer cells
can lose their sensitivity to the anti-proliferative effects of Ca2+ [38],
the causes for which are multifactorial and not completely understood.
It has been reported that several calcium-activated, metastasis-
promoting proteins (for e.g. members of the S100 protein family)
become overexpressed during tumor progression [39]. Additionally,
previous studies have shown that cells lacking the CaSR have an aggres-
sive, highly malignant phenotype [21,40,41]. In the present study, we
Fig. 6. Impact of the CaSR on cell viability, apoptosis and differentiation in stably transfectedHT29 cells. (A) Proliferation (n=4) and (B) apoptosis (n=3)weremeasured inHT29CaSR-WT,
HT29CaSR-DN or the HT29EMP cells. (C) Gene expression of intestinal differentiation markers, SI and CDX2 was measured by qRT-PCR (n = 3). Bars represent means ± SEM. Statistical
signiﬁcance was determined using ANOVA followed by Tukey's post-test. Asterisks above bars indicate signiﬁcant differenceswithin groups compared with the respective vehicle control
(striped bar), whereas hash tags indicate signiﬁcant differences between groups compared with HT29EMPTY cells. **p b 0.05, ***p b 0.001 and ###p b 0.001.
2165A. Aggarwal et al. / Biochimica et Biophysica Acta 1853 (2015) 2158–2167evaluated whether reintroducing the CaSR could restore sensitivity to
the anti-proliferative effects of calcium. Therefore, we investigated the
impact of the wild-type CaSR and a dominant negative mutant CaSR
(R185Q) on the tumorigenic potential of two well characterized-CRC
cell lines: the more differentiated Caco2-15 and the highly tumorigenic
HT29 [26,28,29]. Caco2-15 cells, derived from a well-differentiated
adenocarcinoma express detectable levels of endogenous CaSR. These
cells differentiate spontaneously in culture and are sensitive to the anti-
proliferative, pro-differentiating effects of calcium [4]. HT29 is a highly
malignant, adenocarcinoma-derived cell line with negligible levels of
endogenous CaSR expression making these cells a good model to assesswhether ectopic CaSR expression and function would restore their
sensitivity to the anti-tumorigenic effects of Ca2+. Our data shows
that in Caco2-15 cells CaSR activation confers a differentiation boost;
however in HT29 cells this effect is not as robust. In HT29 cells the
main role of the CaSR seems to be stimulation of apoptosis, whereas in
Caco2-15 cells the pro-differentiating effects seem to prevail.
We further conﬁrmed the role of CaSR in mediating the anti-
proliferative, pro-differentiating and pro-apoptotic effects of Ca2+ by
treating cells with the speciﬁc allosteric modulators of the CaSR: NPS
R-568 or NPS 2143. Treatment with NPS R-568 enhanced the effect of
Ca2+, the primary CaSR agonist, in the cell lines expressing endogenous
2166 A. Aggarwal et al. / Biochimica et Biophysica Acta 1853 (2015) 2158–2167or exogenouswild-type CaSR suggesting that cells expressing functional
CaSR could be targeted with synthetic positive allosteric modulators, as
adjuvant treatment supporting traditional chemotherapy. Singh and
colleagues have shown that in the presence of the CaSR, 5-Fluorouracil
(drug of choice in CRC treatment) is more effective in vitro. Thus, specif-
ically modiﬁed CaSR-pharmacochaperones that are ineffectively
absorbed in the small intestine, but active in the colon, could be used
to be highly effective locally without signiﬁcantly affecting systemic
Ca2+ homeostasis.
The calcilytic, NPS 2143 enhanced proliferation, and inhibited
apoptosis even in HT29EMP cells which have negligible endogenous ex-
pression of theCaSR. These unexpected results suggest that the calcilytic
must have additional effects besides modulating CaSR activity. Interest-
ingly, 1 μMNPS 2143 upregulated endogenous CaSR expression in HT29
cells at both mRNA and protein levels (Fig. 7). Whether the effects seen
in the functional data are due to the calcilytic targeting the newly
synthesized endogenous CaSR, or are off-target effects (or both) needs
further clariﬁcation.
In a recent case–control study, Dong et al. demonstrated a signiﬁcant
association between four CaSR gene variants, and the risk of develop-
ment of carcinomas in the proximal colon [42]. The generation of
transfectants over-expressing the dominant negative CaSR mutant
R185Q allowed us to study the potential roles of the inactivating CaSR
mutants in colorectal tumorigenesis. The R185Qmutant was previously
identiﬁed in patients with Familial Hypocalciuric Hypercalcemia (FHH)
[43] and neonatal severe hyperparathyroidism (NSHPT) [44]. A case re-
port has previously shown that a patient with NSHPT bearing an R185Q
mutation was successfully treated with cinacalcet, an FDA approved
positive allosteric modulator of CaSR [45].
HT29CaSR-DN and Caco2-15CaSR-DN cells expressed the receptor at the
cell surface [46], however they were resistant to the tumor protective
actions of Ca2+ consistent with previous ﬁndings that the residue
R185 lies in close proximity to one of the proposed Ca2+ binding sites
[47], and that dimerization of mutant R185Q with wild-type CaSR re-
duces functionality of the latter [46]. In our experiments with Caco2-
15 cells transfected with the CaSR-DN mutant, the treatment with NPS
R-568 corrected the effect of the mutation and was able to reduce the
malignant phenotype by increasing differentiation and reducing prolif-
eration. Taken together, these results point towards a novel CRC risk
group: patients with loss-of-function CaSRmutations, and suggest a po-
tential role for CaSR modulators in treatment of disorders besides those
of the parathyroid. Our subsequent goal is to evaluate whether patients
with FHH and NSHPT who harbor inactivating mutations of the CaSR,
indeed have increased CRC risk.
Our work provides evidence based on human patient data as well
as mechanistic data from cell lines and animal models that the CaSRH
T2
9E
M
P
Control NPS 2143
CaSR DAPI
A
Fig. 7.CaSRexpression inHT29EMP cells treatedwithNPS2143. Expression of CaSRprotein deter
in 1.8mM calcium and treated with 1 μMNPS 2143. Vehicle-treated cells were used as control.
with vehicle control. **p b 0.05.mediates the anti-neoplastic effects of calcium in the colon and protects
the colonic epithelial cell frommalignant transformation.We found that
the stable over-expression of the functional CaSR affected several hall-
marks of cancer cells: reduced growth, increased differentiation and in-
duced apoptosis. We show for the ﬁrst time that inactivating CaSR
mutations could be a risk factor for CRC. Manipulation of CaSR expres-
sion and chemical modulation of CaSR function in cell lines demon-
strates that the CaSR is indeed a functionally relevant target so that
strategies aiming at either inducing CaSR expression or positively mod-
ulating its function are predicted to reduce cancer incidence. These data
provide a rationale for suitably designed prospective trials using explic-
itly designed synthetic modulators that target the CaSR in colorectal
cancer patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.02.011.
Transparency documents
The Transparency documents associated with this article can be
found, in the online version.
Acknowledgements
The authors would like to acknowledge Dr. Ildiko Mesteri for assis-
tance with patient material. The authors are grateful to Prof. Arthur
Conigrave and Dr. Charlotte Gröschel for critical reading of the manu-
script. The authors would like to thank Teresa Manhardt and Rita Lang
for their technical assistance and EU Marie Curie ITN (FP7-264663 to
EK, RM, and SBP), Austrian Science Fund (FWF, P22200-B11 to EK)
and Herzfelder'sche Familienstiftung (AP00422OFF to EK) for ﬁnancial
support.
References
[1] C. Garland, R.B. Shekelle, E. Barrett-Connor, M.H. Criqui, A.H. Rossof, O. Paul, Dietary
vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in
men, Lancet 1 (8424) (1985) 307–309.
[2] D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002, CA Cancer J.
Clin. 55 (2) (2005) 74–108.
[3] M.M. Center, A. Jemal, R.A. Smith, E. Ward, Worldwide variations in colorectal
cancer, CA Cancer J. Clin. 59 (6) (2009) 366–378.
[4] E. Kállay, E. Bajna, F. Wrba, S. Kriwanek, M. Peterlik, H.S. Cross, Dietary calcium and
growth modulation of human colon cancer cells: role of the extracellular calcium-
sensing receptor, Cancer Detect. Prev. 24 (2) (2000) 127–136.
[5] E. Kállay, G. Bises, E. Bajna, C. Bieglmayer, W. Gerdenitsch, I. Steffan, et al., Colon-
speciﬁc regulation of vitamin D hydroxylases—a possible approach for tumor
prevention, Carcinogenesis 26 (9) (2005) 1581–1589.
[6] J.F. Whitﬁeld, Calcium, calcium-sensing receptor and colon cancer, Cancer Lett. 275
(1) (2009) 9–16.CaSR expression
0
1
2
3
4
Control NPS 2143
**
r
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
o
n
B
minedby immunoﬂuorescence (A) andmRNAdetermined byqRT-PCR (B) in cells cultured
White bar represents 50 μm. Asterisks above bars indicate signiﬁcant difference compared
2167A. Aggarwal et al. / Biochimica et Biophysica Acta 1853 (2015) 2158–2167[7] R. Van der Meer, H.T. De Vries, Differential binding of glycine- and taurine-
conjugated bile acids to insoluble calcium phosphate, Biochem. J. 229 (1) (1985)
265–268.
[8] H.L. Newmark, M.J. Wargovich, W.R. Bruce, Colon cancer and dietary fat, phosphate,
and calcium: a hypothesis, J. Natl. Cancer Inst. 72 (6) (1984) 1323–1325.
[9] V. Fedirko, R.M. Bostick, W.D. Flanders, Q. Long, E. Sidelnikov, A. Shaukat, et al.,
Effects of vitamin d and calcium on proliferation and differentiation in normal
colon mucosa: a randomized clinical trial, Cancer Epidemiol. Biomarkers Prev. 18
(11) (2009) 2933–2941.
[10] V. Fedirko, R.M. Bostick, W.D. Flanders, Q. Long, A. Shaukat, R.E. Rutherford, et al.,
Effects of vitamin D and calcium supplementation on markers of apoptosis in
normal colon mucosa: a randomized, double-blind, placebo-controlled clinical
trial, Cancer Prev. Res. (Phila.) 2 (3) (2009) 213–223.
[11] M. Lipkin, H. Newmark, Effect of added dietary calcium on colonic epithelial-cell
proliferation in subjects at high risk for familial colonic cancer, N. Engl. J. Med. 313
(22) (1985) 1381–1384.
[12] T.U. Ahearn, M.L. McCullough, W.D. Flanders, Q. Long, E. Sidelnikov, V. Fedirko, et al.,
A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on
markers of their metabolism in normalmucosa of colorectal adenoma patients, Can-
cer Res. 71 (2) (2011) 413–423.
[13] E.M. Brown, G. Gamba, D. Riccardi, M. Lombardi, R. Butters, O. Kifor, et al., Cloning
and characterization of an extracellular Ca(2+)-sensing receptor from bovine para-
thyroid, Nature 366 (6455) (1993) 575–580.
[14] G.E. Breitwieser, Pharmacoperones and the calcium sensing receptor: exogenous
and endogenous regulators, Pharmacol. Res. 83 (2014) 30–37.
[15] E.F. Nemeth, Allosteric modulators of the extracellular calcium receptor, Drug
Discov. Today Technol. 10 (2) (2013) e277–e284.
[16] E. Kállay, E. Bonner, F. Wrba, R.V. Thakker, M. Peterlik, H.S. Cross, Molecular and
functional characterization of the extracellular calcium-sensing receptor in human
colon cancer cells, Oncol. Res. 13 (12) (2003) 551–559.
[17] O. Rey, W. Chang, D. Bikle, N. Rozengurt, S.H. Young, E. Rozengurt, Negative cross-
talk between calcium-sensing receptor and β-catenin signaling systems in colonic
epithelium, J. Biol. Chem. 287 (2) (2012) 1158–1167.
[18] S.C. Brennan, U. Thiem, S. Roth, A. Aggarwal, I.Sh. Fetahu, S. Tennakoon, et al.,
Calcium sensing receptor signalling in physiology and cancer, Biochim. Biophys.
Acta 1833 (7) (2013) 1732–1744.
[19] I.S. Fetahu, J. Höbaus, A. Aggarwal, D.M. Hummel, S. Tennakoon, I. Mesteri, et al.,
Calcium-sensing receptor silencing in colorectal cancer is associated with promoter
hypermethylation and loss of acetylation on histone 3, Int. J. Cancer 135 (9) (2014)
2014–2023.
[20] Y. Sheinin, E. Kállay, F. Wrba, S. Kriwanek, M. Peterlik, H.S. Cross, Immunocytochem-
ical localization of the extracellular calcium-sensing receptor in normal and
malignant human large intestinal mucosa, J. Histochem. Cytochem. 48 (5) (2000)
595–602.
[21] N. Bhagavathula, A.W. Hanosh, K.C. Nerusu, H. Appelman, S. Chakrabarty, J. Varani,
Regulation of E-cadherin and beta-catenin by Ca2+ in colon carcinoma is dependent
on calcium-sensing receptor expression and function, Int. J. Cancer 121 (7) (2007)
1455–1462.
[22] K. Hizaki, H. Yamamoto, H. Taniguchi, Y. Adachi, M. Nakazawa, T. Tanuma, et al.,
Epigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis,
Mod. Pathol. 24 (6) (2011) 876–884.
[23] N. Singh, G. Liu, S. Chakrabarty, Isolation and characterization of calcium sensing
receptor null cells: a highlymalignant and drug resistant phenotype of colon cancer,
Int. J. Cancer 132 (9) (2013) 1996–2005.
[24] S.J. Quinn, A.R. Thomsen, J.L. Pang, L. Kantham, H. Bräuner-Osborne, M. Pollak, et al.,
Interactions between calcium and phosphorus in the regulation of the production of
ﬁbroblast growth factor 23 in vivo, Am. J. Physiol. Endocrinol. Metab. 304 (3) (2013)
E310–E320.
[25] J. Höbaus, D.M. Hummel, U. Thiem, I.S. Fetahu, A. Aggarwal, L. Müllauer, et al.,
Increased copy-number and not DNA hypomethylation causes overexpression of
the candidate proto-oncogene CYP24A1 in colorectal cancer, Int. J. Cancer 133 (6)
(2013) 1380–1388.
[26] J.F. Beaulieu, A. Quaroni, Clonal analysis of sucrase-isomaltase expression in the
human colon adenocarcinoma Caco-2 cells, Biochem. J. 280 (Pt 3) (1991) 599–608.
[27] M.J. Pillaire, J. Selves, K. Gordien, P.A. Gourraud, P.A. Gouraud, C. Gentil, et al., A ‘DNA
replication’ signature of progression and negative outcome in colorectal cancer,
Oncogene 29 (6) (2010) 876–887.[28] I. Chantret, A. Barbat, E. Dussaulx, M.G. Brattain, A. Zweibaum, Epithelial polarity,
villin expression, and enterocytic differentiation of cultured human colon carcinoma
cells: a survey of twenty cell lines, Cancer Res. 48 (7) (1988) 1936–1942.
[29] C.J. Marshall, L.M. Franks, A.W. Carbonell, Markers of neoplastic transformation in
epithelial cell lines derived from human carcinomas, J. Natl. Cancer Inst. 58 (6)
(1977) 1743–1751.
[30] J.L. Wang, Y.W. Lin, H.M. Chen, X. Kong, H. Xiong, N. Shen, et al., Calcium prevents
tumorigenesis in a mouse model of colorectal cancer, PLoS One 6 (8) (2011)
e22566.
[31] E. Kállay, O. Kifor, N. Chattopadhyay, E.M. Brown, M.G. Bischof, M. Peterlik, et al.,
Calcium-dependent c-myc proto-oncogene expression and proliferation of Caco-2
cells: a role for a luminal extracellular calcium-sensing receptor, Biochem. Biophys.
Res. Commun. 232 (1) (1997) 80–83.
[32] J.M. Jessup, P.T. Lavin, C.W. Andrews, M. Loda, A. Mercurio, B.D. Minsky, et al.,
Sucrase–isomaltase is an independent prognostic marker for colorectal carcinoma,
Dis. Colon Rectum 38 (12) (1995) 1257–1264.
[33] A.J. Markowitz, G.D. Wu, A. Bader, Z. Cui, L. Chen, P.G. Traber, Regulation of lineage-
speciﬁc transcription of the sucrase–isomaltase gene in transgenic mice and cell
lines, Am. J. Physiol. 269 (6 Pt 1) (1995) G925–G939.
[34] I. Sturm, C.H. Köhne, G. Wolff, H. Petrowsky, T. Hillebrand, S. Hauptmann, et al.,
Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative
prognostic factor in patients with resected liver metastases, J. Clin. Oncol. 17 (5)
(1999) 1364–1374.
[35] A. Jansson, X.F. Sun, Bax expression decreases signiﬁcantly from primary tumor to
metastasis in colorectal cancer, J. Clin. Oncol. 20 (3) (2002) 811–816.
[36] S.X. Cheng, Y.L. Lightfoot, T. Yang, M. Zadeh, L. Tang, B. Sahay, et al., Epithelial
CaSR deﬁciency alters intestinal integrity and promotes proinﬂammatory immune
responses, FEBS Lett. 588 (22) (2014) 4158–4166.
[37] R.J. MacLeod, Extracellular calcium-sensing receptor/PTH knockout mice colons
have increased Wnt/β-catenin signaling, reduced non-canonical Wnt signaling,
and increased susceptibility to azoxymethane-induced aberrant crypt foci, Lab.
Investig. 93 (5) (2013) 520–527.
[38] R.R. Buras, M. Shabahang, F. Davoodi, L.M. Schumaker, K.J. Cullen, S. Byers, et al., The
effect of extracellular calcium on colonocytes: evidence for differential responsive-
ness based upon degree of cell differentiation, Cell Prolif. 28 (4) (1995) 245–262.
[39] A.R. Bresnick, D.J. Weber, D.B. Zimmer, S100 proteins in cancer, Nat. Rev. Cancer 15
(2) (2015) 96–109.
[40] N. Singh, G. Liu, S. Chakrabarty, Cellular responses to TGFβ and TGFβ receptor
expression in human colonic epithelial cells require CaSR expression and function,
Cell Calcium 53 (5–6) (2013) 366–371.
[41] G. Liu, X. Hu, S. Chakrabarty, Vitamin D mediates its action in human
colon carcinoma cells in a calcium-sensing receptor-dependent manner:
downregulates malignant cell behavior and the expression of thymidylate
synthase and survivin and promotes cellular sensitivity to 5-FU, Int. J. Cancer
126 (3) (2010) 631–639.
[42] L.M. Dong, C.M. Ulrich, L. Hsu, D.J. Duggan, D.S. Benitez, E. White, et al., Genetic
variation in calcium-sensing receptor and risk for colon cancer, Cancer Epidemiol.
Biomarkers Prev. 17 (10) (2008) 2755–2765.
[43] M.R. Pollak, E.M. Brown, Y.H. Chou, S.C. Hebert, S.J. Marx, B. Steinmann, et al.,
Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric
hypercalcemia and neonatal severe hyperparathyroidism, Cell 75 (7) (1993)
1297–1303.
[44] M. Bai, S.H. Pearce, O. Kifor, S. Trivedi, U.G. Stauffer, R.V. Thakker, et al., In vivo and
in vitro characterization of neonatal hyperparathyroidism resulting from a de novo,
heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal
calcium homeostasis as a cause of secondary hyperparathyroidism in familial
benign hypocalciuric hypercalcemia, J. Clin. Invest. 99 (1) (1997) 88–96.
[45] C.M. Reh, G.N. Hendy, D.E. Cole, D.D. Jeandron, Neonatal hyperparathyroidismwith a
heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical beneﬁt
from cinacalcet, J. Clin. Endocrinol. Metab. 96 (4) (2011) E707–E712.
[46] M. Bai, S. Quinn, S. Trivedi, O. Kifor, S.H. Pearce, M.R. Pollak, et al., Expression
and characterization of inactivating and activating mutations in the human Ca2+
o-sensing receptor, J. Biol. Chem. 271 (32) (1996) 19537–19545.
[47] Y. Huang, Y. Zhou, A. Castiblanco, W. Yang, E.M. Brown, J.J. Yang, Multiple
Ca(2+)-binding sites in the extracellular domain of the Ca(2+)-sensing recep-
tor corresponding to cooperative Ca(2+) response, Biochemistry 48 (2) (2009)
388–398.
